Microfat and Lipogems: one procedure, and the data runs to four years.

MICROFAT / LIPOGEMS — MICROFRAGMENTED ADIPOSE TISSUE

Microfat and Lipogems are the same concept: your own fat, mechanically broken down and rinsed, then placed back into the joint. One procedure, and the best follow-up data runs to four years.

One injection, and the clock runs in years

This is the number that separates fat from everything else on this website. In a prospective series of patients with symptomatic knee osteoarthritis who had already failed conservative treatment, a single microfragmented fat injection was still delivering a clinically effective result in 68% of them at four years.

Set that against how platelet-rich plasma behaves. PRP delivers a bolus of growth factors that are consumed over weeks; the effect is real, and for most joints it is measured in months and then repeated. Fat is not a bolus. It is a graft of living tissue with its own scaffold, and it stays where it is put.

That difference in kind is why the head-to-head trials are more encouraging than they first appear. A randomized comparison found a single microfat injection did not differ from PRP for clinical outcomes out to 24 months — and the honest way to read that is not “no better”. It is that one procedure held its own against a treatment normally given as a series, over two years.

What is actually in it, and why fat rather than marrow

Adipose tissue is the most cell-dense tissue you can harvest from a conscious patient through a small cannula under local anesthetic. The regenerative population does not live in the fat cells themselves but in the perivascular tissue around them — the vessel walls threading through the fat — and fat carries far more of that per gram than marrow does.

The processing is deliberately mechanical. Tissue is fragmented and rinsed of oil and blood, and nothing is enzymatically digested, cultured or expanded. What comes back is a paste of intact fat clusters with their vascular niche and scaffolding preserved. That matters twice over: it keeps the procedure inside minimal-manipulation rules as a same-day autologous treatment, and it preserves the structure that lets the graft sit in the joint rather than disperse from it.

Lipogems [microfragmented fat] is the best-known device for doing this in the United States, and it is where much of the published safety and outcome data comes from. The brand names the processing system, not a different substance — which is why microfat, micro-fragmented adipose tissue, MFAT and Lipogems all describe the same thing on this page.

Where it does its best work: the joints PRP struggles with

The case for fat strengthens exactly where the case for plasma weakens.

Moderate-to-severe disease. A prospective cohort treating severe knee and shoulder osteoarthritis reported significant improvement across every outcome measure from two weeks, maintained at fifty-two weeks. That is the population where a plasma preparation typically produces a shorter and smaller effect.

Against a steroid. In a randomized trial of 480 patients spanning Kellgren–Lawrence grades 2 through 4, patients who received a single cell-based injection were more likely to be classified as responders at twelve months than those who received a corticosteroid — without the cartilage cost that repeated steroid carries, which is set out on PRP compared with cortisone.

Beyond the knee. The knee has most of the evidence, but it is not the only joint. A prospective series in hip osteoarthritis using a single ultrasound-guided injection found significant improvement in pain and function sustained across every follow-up point to a year, and the shoulder data sits inside the severe-disease cohort above. For the hip in particular — a deep joint that cannot be reached reliably by feel — the combination of a durable graft and image guidance is a sensible pairing. See PRP for hip osteoarthritis.

The one honest limitation, and why it argues for treating here

Two independent analyses have found the same thing: outcomes fall as body mass index rises. A regression within the severe-OA cohort found an inverse correlation between BMI and improvement in the knee, and a secondary analysis of a randomized PRP-versus-microfat trial examined the same relationship directly.

Most clinics offering this will not tell you that, and the ones that do tend to present it as a reason to turn people away. It is neither. It is the clearest possible evidence that an orthobiologic performs to the standard of the terrain you inject it into. Insulin resistance and metabolic inflammation glycate collagen, degrade microvascular delivery and hold tissue in a degradative state — the same mechanism, described in full on metabolic health and tissue repair, that decides how any of this performs.

That is the argument for having it done somewhere that treats the metabolic picture at the same visit rather than ignoring it. Reading a bloodwork panel is not an add-on service here; it is the reason the biology gets a fair chance. A practice that injects fat into an untreated metabolic problem and calls the result the treatment’s ceiling has confused the tissue with the terrain.

Who this suits

• Anyone who wants one procedure rather than a series. The durability data is the reason to choose it, and a single appointment against three is a real difference in a working life.
• Moderate to advanced degeneration, where a plasma preparation has less to work with and the four-year figures were earned.
• A joint that responded to PRP but not enough — partial, genuine, and short of what was needed.
• Anyone deferring a joint replacement and wanting the years in between to be worth something. What that buys is set out on PRP compared with surgery.

It does not suit someone expecting it to do what an arthroplasty does. It rebuilds no cartilage and we will not claim it does.

What the day involves

A small area of the abdomen or flank is anesthetized and tissue is drawn through a cannula. It is longer and more uncomfortable than a blood draw, and the honest warning is that the harvest site is usually sorer than the joint for the first few days. That is the price of the durability, and it is worth naming before you agree to it rather than afterward.

Processing happens in the room at the same visit. Nothing is shipped anywhere, nothing is stored, and nothing is cultured. The injection is placed under ultrasound or fluoroscopic guidance, because a preparation this viscous delivered by landmark is not reliably where you believe it is. The recovery timeline applies as written, with a second sore site added to it.

Risk, on the record

A systematic review of adverse events across cell-based knee injections — marrow, adipose, stromal vascular fraction and cultured products — found the complication profile favorable, with serious events uncommon. Everything on the general risks page applies, plus the two things particular to a graft: a second wound with its own small infection and bleeding risk, and more donor-site trauma than the phrase “a little fat” leads people to expect.

One thing this is not: a stem cell treatment, whatever the clinic down the road is calling it. Nothing is counted, cultured or expanded, and the honest description is a minimally manipulated autologous tissue graft. The distinction is drawn on PRP compared with stem cell treatments, and it matters more than the marketing suggests.

What people ask about a fat-based treatment

Is microfat the same as Lipogems?

Yes. Lipogems is the processing system most widely used in the United States and the source of much of the published data; microfat, micro-fragmented adipose tissue and MFAT are the generic terms for the same tissue prepared the same way. There is no substance difference.

Is it better than PRP?

It is more durable, which is the difference that matters. Head-to-head trials show a single microfat injection holding level with PRP out to 24 months, and a separate series had 68% of patients still doing well at four years from one treatment. For a straightforward earlier-stage joint, PRP remains an excellent and less demanding option.

How many injections will I need?

Usually one. That is the central practical argument for it, and it is why the harvest is worth tolerating.

Does it hurt more than PRP?

Yes, and at the donor site rather than the joint. Expect the abdomen or flank to be the sorer area for several days. The joint itself behaves much like any other guided injection.

Does my weight affect whether it works?

It does, and we would rather say so. Outcomes fall as BMI rises in more than one analysis. That is not a reason to decline treatment; it is the reason the metabolic picture is assessed and treated alongside it here rather than left as an unexamined ceiling on your result.

Related reading

• Bone marrow aspirate concentrate
• PRP compared with BMAC
• PRP compared with stem cell treatments
• Metabolic health and tissue repair
• PRP for knee osteoarthritis
• Recovery timeline